The majority of the mutants have a deletion in the N-terminal ligand-binding region between amino acids 6 and 273 named EGFRvIII (mutated EGFR that can induce transformations of surrounding cells to GBM-like phenotypes), which can result in ligand-independent activation of EGFR [38]. This evidence concerns the gene EGFR and glioblastoma.